A drug policy researcher is proposing a suite of changes to overhaul the Multi-Criteria Drug Harm Scale, which informs drug policies across Europe.
The project will investigate the pain relief properties of CBD oil by exploring its mechanism of action in pain and associated depression and anxiety.
A team at Medicinal Genomics have successfully sequenced the cannabis genome at 640kb N50, representing a 28% improvement on the Human Genome Project standard.
A list of the proposed rule changes is expected to be published on or after October 31 2018 and will address issues like THC serving limits, packaging requirements, and contaminant testing.
The analyzer is a hybrid testing machine which combines the use of near-infrared spectroscopy technology with visual image analysis and machine learning to accurately characterize the potency of a cannabis sample.
Anandia is the Canadian leader in independent third-party testing and was awarded "Top Testing Lab" at the 2017 Lift Canadian Cannabis Awards.
With only a patchwork of state cannabis laws currently in existence, these new recommendations offer a unified federal framework to help optimize the care of patients across the country.
According to statistics provided by California’s Bureau of Cannabis Control, 20% of all cannabis products analyzed by August 6, 2018, received a failed certificate of analysis.
The media is claiming that long-term cannabis use could result in damage to the human brain based on findings from a research study that used neither cannabis or humans.